What does NIPTIFY analyse?

NIPTIFY determines the risk of four of the most common chromosomal diseases in the foetus:
Down syndrome
(trisomy 21)
Edwards syndrome
(trisomy 18)
Patau syndrome
(trisomy 13)
Turner syndrome (45,X)
If desired, the gender of the foetus can also be determined.

What is NIPTIFY?

The most up-to-date method of screening for chromosomal diseases
Part of national prenatal screening programme in Estonia

High accuracy helps avoid unnecessary invasive procedures

Analysis of foetal DNA from maternal blood sample makes it safe for both the baby and the mother

Gives peace of mind to pregnant families

How to test?

The NIPTIFY test is performed from week 10 of pregnancy
A doctor, midwife or nurse takes a blood sample
The blood sample is delivered to Precision Medicine Laboratory in Tartu, Estonia

The results of the test are communicated to the doctor or midwife within ten working days at the latest
NIPTIFY results are given and explained to you by your doctor or midwife

We developed NIPTIFY so that a modern medical service would be available to pregnant women as precise and timely as possible.

Why choose NIPTIFY?


for both foetus and mother


Assesses the risk of chromosomal diseases


From 10+ weeks of pregnancy


best value for money

  • NIPTIFY is suitable for all pregnant women. The test is taken by pregnant women of all ages who want to test the foetus for possible chromosomal diseases.

  • NIPTIFY is reliable. The test determines the risk of developing chromosomal disease with more than 99% accuracy. In the case of a high-risk result, the doctor will direct the pregnant woman for further studies.

  • NIPTIFY is safe. The test is done on the mother’s blood sample. It does not interfere with the foetal environment and does not endanger the course of pregnancy.

  • NIPTIFY saves time. The test can be done in 10+ weeks of pregnancy. Finding an early foetal chromosome disease gives the woman an informed choice.

  • NIPTIFY tests are conducted in Estonia, EU. The test was developed in collaboration with universities in Estonia and Belgium.

  • Regardless of the NIPTIFY test results, further screening, including ultrasound, should not be abandoned.

NIPTIFY analyzes four of the most prevalent chromosomal conditions, which combined, cover approximately 80% of all congenital chromosomal abnormalities. In addition to Down, Edwards and Patau syndrome, NIPTIFY also reports the Turner syndrome, which is an anomaly of the X-chromosome and can occur in females only. The chart below is a summary of different NIPT tests offered in Estonia and the range of chromosomal abnormalities that they test for out of all possible versions. 

We are working hard to offer you the NIPT test with the best quality and price ratio!

The argument “all my three children are healthy” may no longer apply to the fourth.

Partners of NIPTIFY